Literature DB >> 28353185

PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside.

Catharine C Bulik1, Justin C Bader2, Li Zhang3, Scott A Van Wart2, Christopher M Rubino2, Sujata M Bhavnani2, Kim L Sweeney2, Paul G Ambrose2.   

Abstract

Antimicrobial stewardship programs face many challenges, one of which is a lack of guidance regarding antimicrobial dose, interval, and duration. There is no tool that considers patient demographic, pathogen susceptibility, and pharmacokinetic-pharmacodynamic (PK-PD) targets for efficacy in order to evaluate appropriate antimicrobial dosing regimens. The PK-PD Compass, an educational mobile application, was developed to address this unmet need. The application consists of a Monte Carlo simulation algorithm which integrates pharmacokinetic (PK) and PK-PD data, patient-specific characteristics, and pathogen susceptibility data. Through the integration of these data, the application allows practitioners to assess the percent probability of PK-PD target attainment for 35 intravenous antimicrobial agents across 29 infection categories. Population PK models for each drug were identified, evaluated, and refined as needed. Susceptibility breakpoints were based upon FDA and CLSI criteria. By incorporating these data into one interface, clinicians can select the infection, pathogen, and antimicrobial agents of interest and obtain the percent probability of PK-PD target attainment for each regimen based upon patient-specific characteristics. The antimicrobial dosing regimens provided include those recommended by standard guidelines and reference texts. However, unlike these references, potential choices are prioritized based on percent probabilities of PK-PD target attainment. Such data will educate clinicians on selecting optimized antibiotic regimens through the lens of PK-PD.

Entities:  

Keywords:  Antimicrobial stewardship; Pharmacodynamics; Pharmacokinetics; Software

Mesh:

Substances:

Year:  2017        PMID: 28353185     DOI: 10.1007/s10928-017-9518-0

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  31 in total

Review 1.  International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.

Authors:  Kalpana Gupta; Thomas M Hooton; Kurt G Naber; Björn Wullt; Richard Colgan; Loren G Miller; Gregory J Moran; Lindsay E Nicolle; Raul Raz; Anthony J Schaeffer; David E Soper
Journal:  Clin Infect Dis       Date:  2011-03-01       Impact factor: 9.079

2.  Population pharmacokinetics of intravenous levofloxacin 500 mg/day dosage in infected patients.

Authors:  Yuan Zhang; Li-Qin Zhu; Nan Wang; Xuequn Zhao; Wenjie Yang; Shuangmin Ji; Liying Sun
Journal:  Pharmazie       Date:  2014-07       Impact factor: 1.267

3.  Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America.

Authors:  Tamar F Barlam; Sara E Cosgrove; Lilian M Abbo; Conan MacDougall; Audrey N Schuetz; Edward J Septimus; Arjun Srinivasan; Timothy H Dellit; Yngve T Falck-Ytter; Neil O Fishman; Cindy W Hamilton; Timothy C Jenkins; Pamela A Lipsett; Preeti N Malani; Larissa S May; Gregory J Moran; Melinda M Neuhauser; Jason G Newland; Christopher A Ohl; Matthew H Samore; Susan K Seo; Kavita K Trivedi
Journal:  Clin Infect Dis       Date:  2016-04-13       Impact factor: 9.079

4.  Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America.

Authors:  Larry M Baddour; Walter R Wilson; Arnold S Bayer; Vance G Fowler; Ann F Bolger; Matthew E Levison; Patricia Ferrieri; Michael A Gerber; Lloyd Y Tani; Michael H Gewitz; David C Tong; James M Steckelberg; Robert S Baltimore; Stanford T Shulman; Jane C Burns; Donald A Falace; Jane W Newburger; Thomas J Pallasch; Masato Takahashi; Kathryn A Taubert
Journal:  Circulation       Date:  2005-06-14       Impact factor: 29.690

5.  Efficacy of human simulated exposures of ceftaroline against phenotypically diverse Enterobacteriaceae isolates.

Authors:  Seth T Housman; Rebecca A Keel; Jared L Crandon; Gregory Williams; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

6.  Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.

Authors:  Charles A Peloquin; David Jamil Hadad; Lucilia Pereira Dutra Molino; Moises Palaci; W Henry Boom; Reynaldo Dietze; John L Johnson
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

7.  Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.

Authors:  Jared L Crandon; Mary Anne Banevicius; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2008-12-29       Impact factor: 5.191

8.  Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.

Authors:  A Forrest; D E Nix; C H Ballow; T F Goss; M C Birmingham; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

9.  Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America.

Authors:  Joseph S Solomkin; John E Mazuski; John S Bradley; Keith A Rodvold; Ellie J C Goldstein; Ellen J Baron; Patrick J O'Neill; Anthony W Chow; E Patchen Dellinger; Soumitra R Eachempati; Sherwood Gorbach; Mary Hilfiker; Addison K May; Avery B Nathens; Robert G Sawyer; John G Bartlett
Journal:  Clin Infect Dis       Date:  2010-01-15       Impact factor: 9.079

10.  Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae.

Authors:  Scott A Van Wart; Paul G Ambrose; Christopher M Rubino; Tatiana Khariton; Todd A Riccobene; H David Friedland; Ian A Critchley; Sujata M Bhavnani
Journal:  Antimicrob Agents Chemother       Date:  2013-11-25       Impact factor: 5.191

View more
  5 in total

1.  Long-Term Continuous Antimicrobial Resistance Surveillance Among Nosocomial Gram-Negative Bacilli in China from 2010 to 2018 (CMSS).

Authors:  Qi Wang; Zhanwei Wang; Feifei Zhang; Chunjiang Zhao; Bin Yang; Ziyong Sun; Yaning Mei; Feng Zhao; Kang Liao; Dawen Guo; Xiuli Xu; Hongli Sun; Zhidong Hu; Yunzhuo Chu; Yi Li; Ping Ji; Hui Wang
Journal:  Infect Drug Resist       Date:  2020-07-28       Impact factor: 4.003

Review 2.  Key Factors in Effective Patient-Tailored Dosing of Fluoroquinolones in Urological Infections: Interindividual Pharmacokinetic and Pharmacodynamic Variability.

Authors:  Oskar Estradé; Valvanera Vozmediano; Nerea Carral; Arantxa Isla; Margarita González; Rachel Poole; Elena Suarez
Journal:  Antibiotics (Basel)       Date:  2022-05-11

Review 3.  Optimizing antimicrobial use: challenges, advances and opportunities.

Authors:  Timothy M Rawson; Richard C Wilson; Danny O'Hare; Pau Herrero; Andrew Kambugu; Mohammed Lamorde; Matthew Ellington; Pantelis Georgiou; Anthony Cass; William W Hope; Alison H Holmes
Journal:  Nat Rev Microbiol       Date:  2021-06-22       Impact factor: 60.633

Review 4.  β-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: Weighing the Challenges and Opportunities to Assess Clinical Value.

Authors:  Thomas J Dilworth; Lucas T Schulz; Scott T Micek; Marin H Kollef; Warren E Rose
Journal:  Crit Care Explor       Date:  2022-07-05

5.  Microbiological Analysis from a Phase 2 Randomized Study in Adults Evaluating Single Oral Doses of Gepotidacin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae.

Authors:  Nicole E Scangarella-Oman; Mohammad Hossain; Paula B Dixon; Karen Ingraham; Sharon Min; Courtney A Tiffany; Caroline R Perry; Aparna Raychaudhuri; Etienne F Dumont; Jianzhong Huang; Edward W Hook; Linda A Miller
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.